Effects of COX-1 inhibition, TP blockade, or a combination of both on CD40L plaque immunoreactivity. Compared with placebo, a significant decrease in CD40L immunoreactivity was observed in mice receiving SC-560 or BM-573 (*P < .001 versus placebo). However, a further significant reduction compared with those 2 groups was found in the group of mice receiving the combination therapy: *P < .01 versus SC or BM. Results are presented as mean ± SEM.